SI9400024A - Transdermal theraupetic system comprising galathamin as active substance - Google Patents

Transdermal theraupetic system comprising galathamin as active substance Download PDF

Info

Publication number
SI9400024A
SI9400024A SI9400024A SI9400024A SI9400024A SI 9400024 A SI9400024 A SI 9400024A SI 9400024 A SI9400024 A SI 9400024A SI 9400024 A SI9400024 A SI 9400024A SI 9400024 A SI9400024 A SI 9400024A
Authority
SI
Slovenia
Prior art keywords
weight
galantamine
tts according
tts
reservoir layer
Prior art date
Application number
SI9400024A
Other languages
English (en)
Slovenian (sl)
Inventor
Thomas Hille
Lothar Deurer
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of SI9400024A publication Critical patent/SI9400024A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9400024A 1993-01-23 1994-01-21 Transdermal theraupetic system comprising galathamin as active substance SI9400024A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil

Publications (1)

Publication Number Publication Date
SI9400024A true SI9400024A (en) 1994-09-30

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9400024A SI9400024A (en) 1993-01-23 1994-01-21 Transdermal theraupetic system comprising galathamin as active substance

Country Status (26)

Country Link
US (1) US5700480A (fi)
EP (1) EP0680325B1 (fi)
JP (1) JPH08505632A (fi)
KR (1) KR100300477B1 (fi)
AT (1) ATE216240T1 (fi)
AU (1) AU679032B2 (fi)
CA (1) CA2153572C (fi)
CZ (1) CZ287053B6 (fi)
DE (2) DE4301783C1 (fi)
DK (1) DK0680325T3 (fi)
ES (1) ES2176234T3 (fi)
FI (1) FI113744B (fi)
HR (1) HRP940028B1 (fi)
HU (1) HU221165B1 (fi)
IL (1) IL108235A (fi)
MY (1) MY109926A (fi)
NO (1) NO307497B1 (fi)
NZ (1) NZ259857A (fi)
PH (1) PH31473A (fi)
PL (1) PL175083B1 (fi)
PT (1) PT680325E (fi)
SI (1) SI9400024A (fi)
SK (1) SK281339B6 (fi)
WO (1) WO1994016707A1 (fi)
YU (1) YU48607B (fi)
ZA (1) ZA94414B (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AU3601897A (en) * 1996-07-15 1998-02-09 Alza Corporation Novel formulations for the administration of fluoxetine
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
DE69912311T2 (de) * 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
US7052714B1 (en) * 1999-10-13 2006-05-30 Senju Pharmaceutical Co., Ltd Ophthalmic adhesive preparations for percutaneous adsorption
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
KR101250021B1 (ko) * 2000-05-26 2013-04-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
EP1895995A2 (en) * 2005-05-13 2008-03-12 Alza Corporation Multilayer drug system for the delivery of galantamine
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
CA2815898C (en) 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
EP4054549A4 (en) 2019-11-06 2023-12-06 Smartech Topical, Inc. TOPICAL FORMULATIONS OF CYCLO-OXYGENASE INHIBITORS AND THEIR USE
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (fi) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
ATE183084T1 (de) * 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren

Also Published As

Publication number Publication date
FI953533A (fi) 1995-07-21
HU9501928D0 (en) 1995-09-28
PT680325E (pt) 2002-09-30
HU221165B1 (en) 2002-08-28
WO1994016707A1 (de) 1994-08-04
AU5881794A (en) 1994-08-15
JPH08505632A (ja) 1996-06-18
CZ184295A3 (en) 1996-01-17
NO307497B1 (no) 2000-04-17
HRP940028A2 (en) 1996-06-30
CZ287053B6 (en) 2000-08-16
IL108235A (en) 1996-10-31
KR100300477B1 (ko) 2001-10-22
HRP940028B1 (en) 2000-02-29
DE59410103D1 (de) 2002-05-23
EP0680325A1 (de) 1995-11-08
FI953533A0 (fi) 1995-07-21
SK281339B6 (sk) 2001-02-12
AU679032B2 (en) 1997-06-19
NO952907L (no) 1995-07-21
ES2176234T3 (es) 2002-12-01
HUT72643A (en) 1996-05-28
EP0680325B1 (de) 2002-04-17
CA2153572A1 (en) 1994-08-04
ATE216240T1 (de) 2002-05-15
US5700480A (en) 1997-12-23
IL108235A0 (en) 1994-04-12
KR960700060A (ko) 1996-01-19
DK0680325T3 (da) 2002-08-05
DE4301783C1 (de) 1994-02-03
PL309603A1 (en) 1995-10-30
PH31473A (en) 1998-11-03
FI113744B (fi) 2004-06-15
NZ259857A (en) 1996-03-26
MY109926A (en) 1997-09-30
ZA94414B (en) 1994-08-31
PL175083B1 (pl) 1998-10-30
YU2694A (sh) 1996-10-18
NO952907D0 (no) 1995-07-21
YU48607B (sh) 1998-12-23
CA2153572C (en) 2006-01-03
SK88995A3 (en) 1996-05-08

Similar Documents

Publication Publication Date Title
SI9400024A (en) Transdermal theraupetic system comprising galathamin as active substance
KR950015061B1 (ko) 활성 성분으로서 부프레노르핀을 포함하는 경피 치료 시스템
CA2045290C (en) Plaster with a high content of softening ingredients
ES2848395T3 (es) Parche transdérmico de fentanilo
CA2549516C (en) Percutaneous absorption-type pharmaceutical preparation
JPH041127A (ja) 医療用貼付剤
CA2548864C (en) Percutaneous absorption-type pharmaceutical preparation
JP2000044904A (ja) アクリル系粘着テープおよび経皮吸収製剤
DE19906977C1 (de) Desoxypeganin-TTS und seine Verwendung
DE102011076653A1 (de) Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
KR100732948B1 (ko) 국소마취용 패취
KR100446416B1 (ko) 국소마취용 패치제
KR950703948A (ko) 피부를 통해 피소스티그민을 투여하기 위한 경피치료계, 및 이러한 계의 제조방법(transdermal therapeutic system for administering physostigmin through the skin〈 and a method of producing the system)
WO1993011767A1 (en) Transdermal delivery of (e)-1,2,5,6-tetrahydro-1-methyl-3-pyridine-carboxaldehyde-o-methyloxine hcl and related compounds in the treatment of cognitive disorders and for analgesia